![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2023
Zaienne, Daniel; Isigkeit, Laura; Marschner, Julian A.; Duensing‐Kropp, Silke; Höfner, Georg und Merk, Daniel 
ORCID: https://orcid.org/0000-0002-5359-8128
(2023):
Structural Modification of the Natural Product Valerenic Acid Tunes RXR Homodimer Agonism.
In: ChemMedChem, Bd. 18, Nr. 21
[PDF, 895kB]
ORCID: https://orcid.org/0000-0002-5359-8128
(2023):
Structural Modification of the Natural Product Valerenic Acid Tunes RXR Homodimer Agonism.
In: ChemMedChem, Bd. 18, Nr. 21
[PDF, 895kB]
2022
Helmstaedter, Moritz; Schierle, Simone; Isigkeit, Laura; Proschak, Ewgenij; Marschner, Julian Aurelio und Merk, Daniel
(2022):
Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists.
In: International Journal of Molecular Sciences, Bd. 23, Nr. 17, 10070
Isigkeit, Laura; Chaikuad, Apirat und Merk, Daniel
(2022):
A Consensus Compound/Bioactivity Dataset for Data-Driven Drug Design and Chemogenomics.
In: Molecules, Bd. 27, Nr. 8, 2513
Adouvi, Gustave; Isigkeit, Laura; Lopez-Garcia, Ursula; Chaikuad, Apirat; Marschner, Julian A.; Schubert-Zsilavecz, Manfred und Merk, Daniel
(2022):
Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXR alpha, RXR beta, and RXR gamma.
In: Journal of Medicinal Chemistry, Bd. 66, Nr. 1: S. 333-344
2021
Lang, Alisa; Isigkeit, Laura; Schubert-Zsilavecz, Manfred und Merk, Daniel
(2021):
The Medicinal Chemistry and Therapeutic Potential of LRH-1 Modulators.
In: Journal of Medicinal Chemistry, Bd. 64, Nr. 23: S. 16956-16973